<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209585</url>
  </required_header>
  <id_info>
    <org_study_id>CD-IA-INDP-1056</org_study_id>
    <nct_id>NCT01209585</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>Study to Evaluate Biomarkers in Blood and Synovial Fluid in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the evaluation of blood samples and blood types to&#xD;
      identify functional protein in the joints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of type I IFN signature in the peripheral blood and activation of type I IFN&#xD;
      signaling pathway in synovial fluid (indicating expression of the functional IFN protein in&#xD;
      the joints).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Data Collection and Analyses</measure>
    <time_frame>Study Day 120</time_frame>
    <description>Data analyses on model devlopment to maximize measures of predictive diagnostic accuracy, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RNA Assessment</measure>
    <time_frame>Day 120</time_frame>
    <description>Level of signature protein, messenger RNA or micro RNA in peripheral blood and diseased tissue will also be assessed.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <description>Subject must have RA with inflamed joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoarthritis</arm_group_label>
    <description>Subjects must have OA of the knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudo gout</arm_group_label>
    <description>Subjects must have peusdo-gout of knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Subjects will have visits on Days 1, 30 and 120.</description>
    <arm_group_label>Osteoarthritis</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synovial fluid aspiration</intervention_name>
    <description>Subjects will have visits on Days 1, 30, and 120.</description>
    <arm_group_label>Osteoarthritis</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synovial tissue sample</intervention_name>
    <description>Subjects will have visits on Days 1, 30, and 120.</description>
    <arm_group_label>Osteoarthritis</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or Female Adults aged 18-75 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 through 75 years at time of screening.&#xD;
&#xD;
          -  Written informed consent and any locally required authorization (eg, HIPAA in the&#xD;
             USA), obtained from the subject prior to performing any protocol-related procedures,&#xD;
             including screening evaluations.&#xD;
&#xD;
          -  A diagnosis of: a) Adult onset RA as defined by the 1987 ACR classification criteria&#xD;
             (see Appendix 1), with at least 4 tender and 4 swollen joints at screening (Day 1).&#xD;
             Tender/swollen joints must be a part of the 28-joint count included in the Disease&#xD;
             Assessment Score 28 (DAS28) assessment; b) Osteoarthritis (OA) of the knee or acute&#xD;
             pseudogout attack of the knee.&#xD;
&#xD;
          -  Age ≥ 16 years at the time of onset of RA or onset of OA, pseudogout.&#xD;
&#xD;
          -  Subjects should either not receive oral corticosteroids, or if receiving oral&#xD;
             corticosteroids, need to be on a stable dose of oral prednisone (or equivalent) ≤ 10&#xD;
             mg/day for at least 4 weeks prior to screening (Day 1).&#xD;
&#xD;
          -  Ability and willingness to complete the study until Day 120 as required by the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current inflammatory joint disease other than RA, OA, or pseudogout (eg,&#xD;
             gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme&#xD;
             disease) or other autoimmune disorder (systemic lupus erythematosus, inflammatory&#xD;
             bowel disease, scleroderma, inflammatory myopathy, or overlap syndrome).&#xD;
&#xD;
          -  Any neurological (congenital or acquired), psychiatric, vascular, or systemic disorder&#xD;
             could also affect the evaluation of disease assessments; in particular, joint pain and&#xD;
             swelling.&#xD;
&#xD;
          -  Treatment with IFN-α or IFN-β.&#xD;
&#xD;
          -  Intra-articular, IM, or IV corticosteroid injections within 28 days before screening&#xD;
             (Day 1).&#xD;
&#xD;
          -  Known history of or positive test result for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Serious infection (eg, pneumonia, septicemia) within the 2 months prior to Day 1&#xD;
             visit.&#xD;
&#xD;
          -  Active bacterial or viral infection (which includes ongoing and/or chronic infections&#xD;
             such as hepatitis, tuberculosis, etc).&#xD;
&#xD;
          -  Concomitant use of systemic antiviral, antibiotic, or antifungals for the treatment of&#xD;
             active infection within 28 days of Day 1.&#xD;
&#xD;
          -  History of malignancy or evidence of active or suspected malignancy (with the&#xD;
             exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma&#xD;
             of the uterine cervix &gt; 1 year before randomization into the study).&#xD;
&#xD;
          -  Vaccinations within 4 weeks of Day 1 visit.&#xD;
&#xD;
          -  Concurrent enrollment in another clinical study.&#xD;
&#xD;
          -  Employees of the clinical study site or any other individuals involved with the&#xD;
             conduct of the study, or immediate family members of such individuals.&#xD;
&#xD;
          -  Other unspecified reasons that, in the opinion of the Investigator or medical monitor,&#xD;
             make the subject unsuitable for participation or confound the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Greth, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

